Oral Azacitidine for AML in Transplant-Eligible Patients with Health-Inequality
This study is testing an oral medication called Oral Azacitidine for people with Acute Myeloid Leukemia (AML) who are eligible for a stem cell transplant but face challenges in accessing healthcare or have other social disadvantages. The goal is to see if it's practical for these patients to complete at least four cycles of Oral Azacitidine as a maintenance treatment after their initial AML therapy. You might be able to join if you are 18 or older, have a specific type of AML (non-APL FLT3 negative) that is in complete remission, and have completed your initial treatments. The study plans to enroll 12 participants. The current recruitment status is unclear.
- Study design
- This is a single-institution pilot study that is not randomized and is open-label, meaning everyone knows what treatment is being given. It plans to enroll 12 participants.
- What's involved
- You would take Oral Azacitidine daily for 14 days in 28-day cycles, for up to 6 cycles. The study will assess your progress for at least 4 months.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary goal is measured at 4 months, focusing on the completion rate of at least 4 cycles of treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT06370000
Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality
Recruiting
PHASE4Ages 18+InterventionalTreatmentVirginia Commonwealth UniversityInvestigator-initiated
~12 participants
Updated 2026-05-29 on ClinicalTrials.gov
What's tested:Oral Azacitidine
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Rate of completion of at least 4 cycles an oral maintenance strategy for transplant eligible AML patients in CR who are medically underserved or have a disadvantage in the CDC SDOH domains
Measured over 4 months
Conditions
Where it's being run
1 sites across 1 statesVirginia1
Study leadership
- Keri Maher, DO · PRINCIPAL_INVESTIGATOR · Virginia Commonwealth University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Patients must have histologically or cytologically confirmed non-Acute Promyelocytic (APL) FLT3 negative AML and have completed induction and consolidation as defined by the treating physician and must be in complete response (CR), Complete response with partial hematologic recovery (CRh), or Complete response with incomplete count recovery (CRi) at time of study enrollment
For patients in CR1, AML disease phenotype must be one that is considered for allo HCT in CR1 (intermediate or high risk by European Leukemia Net (ELN), MRD+ CR, slow clearance of MRD) or any AML phenotype (aside from FLT3+ and APL) in CR2 and beyond
Medically eligible for allogeneic hematopoietic cell transplant (allo HCT) as defined by either: treating physician discretion, transplant physician discretion, or hematopoietic cell transplantation-specific Comorbidity index (HCT-CI) index of 5 or less
Age ≥ 18 years
Enrollment must occur within 4 months of completion of therapy
A patient or staff identified health disparity in 1 of the 5 Centers for Disease Control (CDC) defined social determinants of health (SDOH). This may include financial difficulties, lack of caregiver support, difficulties with medical literacy, rurality, appropriate access to health care, lack of an appropriate allogeneic hematopoietic cell transplant (allo HCT) donor, substance abuse
Patient must have adequate organ function defined as: Creatinine clearance (by Cockroft-Gault formula) greater than or equal to 29 mL/min, total bilirubin and aspartate aminotransferase/ alanine transaminase (AST/ALT) ≤ to institutional 2x upper limit of normal (except Gilbert's syndrome, which may enroll if \< 2x patient's baseline total bilirubin)
Eastern Cooperative Oncology Group (ECOG) 0,1,2,3
Ability to take oral medications
No history of malabsorption syndrome which, in the investigator's opinion, may inhibit absorption of oral medications
Women of childbearing potential must consent to effective contraception during study treatment and at least 6 months following the last dose. Women who are breastfeeding are also excluded
Male patients must consent to effective contraception during study and at least 3 months after last dose
Ability to understand and the willingness to sign a written informed consent document
Exclusion
FMS-like tyrosine kinase 3 (FLT3 ITD) or tyrosine kinase domain (TKD) mutation
Uncontrolled central nervous system (CNS) involvement
History of hypersensitivity or allergic reaction to azacitidine or its components
Stem cell transplant within previous 3 months prior to initiation of study therapy
Uncontrolled intercurrent illness or infection
History of prior therapy with oral azacitidine
Female patients who are pregnant or intend to donate eggs during the study or for 6 months after receiving their last dose of study drug
Male patients who intend to donate sperm during the course of this study or for 3 months after last dose
Other malignancy for which the patient is currently receiving therapy (except excisable skin cancer)
Medical, psychological, or social condition that, in the opinion of the investigator, may increase the participant's risk or limit the participant's adherence with study requirements
What this trial measures
- Rate of completion of at least 4 cycles an oral maintenance strategy for transplant eligible AML patients in CR who are medically underserved or have a disadvantage in the CDC SDOH domains4 months
The number of participants that complete at least four cycles of protocol therapy